• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BEVACIZUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • BEVACIZUMAB chembl:CHEMBL1201583 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    RHUMAB-
    R-435
    FKB-238
    12-IGG1
    BS-503A
    HLX-04
    BEVACIZUMAB
    BEVACIZUMAB BETA
    RHUMAB-VEGF
    BI 695502
    RG-435
    AVASTIN
    AVA-1
    HLX04
    ANTIVEGF
    drugbank:00112
    chembl:CHEMBL1201583
    chemidplus:216974-75-3
    pubchem.compound:135329020
    rxcui:253337

    Drug Info:

    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications antineoplastic agent
    FDA Approval Cervical cancer, colorectal cancer, fallopian tube cancer, glioblastoma, non-small cell lung cancer, ovarian cancer, peritoneal cancer, renal cell carcinoma
    Drug Class Therapeutic Antibodies
    Year of Approval 2004
    Drug Class antineoplastic agents
    (8 More Sources)

    Publications:

    Park UC et al., 2014, Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration., Retina
    Chang W et al., 2013, Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population., Mol Vis
    Hagstrom SA et al., 2013, Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)., Ophthalmology
    Tian J et al., 2012, Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population., Pharmacogenomics
    Gampenrieder SP et al., 2017, Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer., Pharmacogenomics J
    Hein A et al., 2015, Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study., Int J Cancer
    Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
    Miyake M et al., 2014, Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia., Ophthalmology
    Abedi F et al., 2013, Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration., Ophthalmology
    Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
    Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
    Gerber et al., 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies., Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Sathornsumetee S et al., 2008, Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan., J Clin Oncol
    Han K et al., 2016, Population pharmacokinetics of bevacizumab in cancer patients with external validation., Cancer Chemother Pharmacol
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer
    Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.
    Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med
    Matsusaka S et al., 2017, CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy., Pharmacogenomics J
    Hanker et al., 2013, Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies., Proc. Natl. Acad. Sci. U.S.A.
    Basho et al., 2017, Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab., JAMA Oncol
    Falchook et al., 2015, Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors., Invest New Drugs
    Rini et al., 2006, Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status., BJU Int.
    Yamasaki et al., 2012, Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy., Cancer Sci.
    Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
    Li M et al., 2018, Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)., Clin Cancer Res
    Said et al., 2013, P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy., Oncotarget
    Wheler et al., 2016, TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics., Mol. Cancer Ther.
    Hochster, 2006, Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer., Semin. Oncol.
    Pander J et al., 2015, Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer., PLoS One
    Jubb et al., 2006, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer., J. Clin. Oncol.
    Erdem-Eraslan et al., 2016, Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial., Cancer Res.
    Tabouret et al., 2016, MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study., Oncotarget
    Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
    Chen JS et al., 2010, A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma., Anticancer Drugs
    Smit EF et al., 2009, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer., J Clin Oncol
    Berger MD et al., 2018, A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab., Clin Cancer Res
    Rosell et al., 2017, Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial., Lancet Respir Med
    Petrelli et al., 2013, KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials., Med. Oncol.
    Venook et al., 2017, Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial., JAMA
    Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Hautamäki A et al., 2013, Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration., Retina
    Ince et al., 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab., J. Natl. Cancer Inst.
    Piao et al., 2016, Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models., Neuro-oncology
    Medina FM et al., 2015, Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration., Ophthalmic Res
    Chen G et al., 2015, Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis., Sci Rep
    Lotery AJ et al., 2013, Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study., Ophthalmology
    Kang HK et al., 2012, Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population., Korean J Ophthalmol
    Smailhodzic D et al., 2012, Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration., Ophthalmology
  • BEVACIZUMAB   CFH

    Interaction Score: 7.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26439641 26411831 24070809 23842101 23584701 23559864 23337555 23204795 22840423 22594510


    Sources:
    PharmGKB

  • BEVACIZUMAB   HTRA1

    Interaction Score: 4.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23842101 23559864 23337555 22594510


    Sources:
    PharmGKB

  • BEVACIZUMAB   THBS2

    Interaction Score: 3.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16365183


    Sources:
    NCI

  • BEVACIZUMAB   ARMS2

    Interaction Score: 3.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22594510


    Sources:
    PharmGKB

  • BEVACIZUMAB   VEGFB

    Interaction Score: 1.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20124951


    Sources:
    ClearityFoundationClinicalTrial PharmGKB

  • BEVACIZUMAB   VEGFA

    Interaction Score: 1.05

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Avastin
    Novel drug target Established target
    Notes

    PMIDs:
    27139155 26100253 25955730 23953100 23149126 20125120 20124951 15705858 11752352 18182667 27329360


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND CIViC PharmGKB TTD

  • BEVACIZUMAB   RGS5

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25069475


    Sources:
    PharmGKB

  • BEVACIZUMAB   MGAT4A

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26222057


    Sources:
    PharmGKB

  • BEVACIZUMAB   VEGFC

    Interaction Score: 1.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20124951


    Sources:
    ClearityFoundationClinicalTrial PharmGKB

  • BEVACIZUMAB   SHMT1

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22044939


    Sources:
    PharmGKB

  • BEVACIZUMAB   GC

    Interaction Score: 0.57

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29208668


    Sources:
    PharmGKB

  • BEVACIZUMAB   GGH

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • BEVACIZUMAB   VHL

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type renal cell carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    16827904 22931246


    Sources:
    JAX-CKB

  • BEVACIZUMAB   EDN1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27139155


    Sources:
    PharmGKB

  • BEVACIZUMAB   MMP9

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26921265


    Sources:
    CIViC

  • BEVACIZUMAB   MTHFR

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 20634689 19307503


    Sources:
    PharmGKB

  • BEVACIZUMAB   PRKCA

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29871907


    Sources:
    PharmGKB

  • BEVACIZUMAB   CXCR4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27503580


    Sources:
    PharmGKB

  • BEVACIZUMAB   MMP2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26921265


    Sources:
    CIViC

  • BEVACIZUMAB   BRAF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Temsirolimus + Doxil
    Indication/Tumor Type ovarian carcinoma
    Response Type sensitive

    PMIDs:
    21216929 19603024 22180495 19571295


    Sources:
    JAX-CKB CIViC

  • BEVACIZUMAB   HRAS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15998951


    Sources:
    NCI

  • BEVACIZUMAB   HSP90AB1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29871907


    Sources:
    PharmGKB

  • BEVACIZUMAB   KRAS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Sorafenib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23828442 21216929 28632865 25363205


    Sources:
    JAX-CKB CIViC

  • BEVACIZUMAB   MET

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Altiratinib + Bevacizumab
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    25363205 26432108 26965451


    Sources:
    JAX-CKB

  • BEVACIZUMAB   CXCL8

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23584701


    Sources:
    PharmGKB

  • BEVACIZUMAB   PIK3CA

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type resistant
    Approval Status Preclinical
    Indication/Tumor Type Her2-receptor positive breast cancer

    PMIDs:
    23940356 27893038 21216929 25363205


    Sources:
    JAX-CKB

  • BEVACIZUMAB   KIT

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Sorafenib
    Indication/Tumor Type gastrointestinal stromal tumor
    Response Type sensitive

    PMIDs:
    25363205


    Sources:
    JAX-CKB

  • BEVACIZUMAB   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BKM120 + Bevacizumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    26432108 23940356


    Sources:
    JAX-CKB

  • BEVACIZUMAB   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Erlotinib
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    28408243


    Sources:
    JAX-CKB

  • BEVACIZUMAB   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type sensitive
    Approval Status Phase III

    PMIDs:
    23670029 27466356 17145525


    Sources:
    JAX-CKB

  • BEVACIZUMAB   IDH1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Lomustine
    Indication/Tumor Type glioblastoma multiforme
    Response Type predicted – sensitive

    PMIDs:
    26762204


    Sources:
    JAX-CKB

  • TEND: BEVACIZUMAB

    • Version: 01-August-2011

    Alternate Names:
    BEVACIZUMAB Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 2004

    Publications:

  • MyCancerGenome: BEVACIZUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    BEVACIZUMAB Generic Name
    AVASTIN Trade Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Cervical cancer, colorectal cancer, fallopian tube cancer, glioblastoma, non-small cell lung cancer, ovarian cancer, peritoneal cancer, renal cell carcinoma

    Publications:

  • TdgClinicalTrial: BEVACIZUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval approved

    Publications:

  • NCI: BEVACIZUMAB

    • Version: 14-September-2017

    Alternate Names:
    C2039 NCI drug code

    Drug Info:

    Publications:
    Jubb et al., 2006, Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer., J. Clin. Oncol.
    Ince et al., 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab., J. Natl. Cancer Inst.

  • JAX-CKB: Bevacizumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Rini et al., 2006, Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status., BJU Int.
    Yamasaki et al., 2012, Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy., Cancer Sci.

  • PharmGKB: bevacizumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tian J et al., 2012, Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population., Pharmacogenomics
    Chang W et al., 2013, Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population., Mol Vis
    Park UC et al., 2014, Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration., Retina

  • CIViC: BEVACIZUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tol J et al., 2009, BRAF mutation in metastatic colorectal cancer., N Engl J Med
    Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer
    Yang et al., 2012, Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer., Cancer Res.

  • TALC: BEVACIZUMAB

    • Version: 12-May-2016

    Alternate Names:
    BEVACIZUMAB Primary Drug Name
    BEVACIZUMAB Drug Generic Name
    AVASTIN Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Bevacizumab

    • Version: 2020.06.01

    Alternate Names:
    D04KBL TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201583

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201583

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: BEVACIZUMAB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21